• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    PCSK9 and triglyceride-rich lipoprotein metabolism

    2015-02-12 10:55:48IrenaDruceHusseinAbujradTeikChyeOoi
    THE JOURNAL OF BIOMEDICAL RESEARCH 2015年6期

    Irena Druce,Hussein Abujrad,Teik Chye Ooi,2,?

    1Clinical Research Laboratory,Division of Endocrinology and Metabolism,Department of Medicine,University of Ottawa, Ottawa,Ontario K1H 8L6,Canada;

    2Chronic Disease Program,Ottawa Hospital Research Institute,The Ottawa Hospital,Ottawa,Ontario K1H 7W9,Canada.

    PCSK9 and triglyceride-rich lipoprotein metabolism

    Irena Druce1,Hussein Abujrad1,Teik Chye Ooi1,2,?

    1Clinical Research Laboratory,Division of Endocrinology and Metabolism,Department of Medicine,University of Ottawa, Ottawa,Ontario K1H 8L6,Canada;

    2Chronic Disease Program,Ottawa Hospital Research Institute,The Ottawa Hospital,Ottawa,Ontario K1H 7W9,Canada.

    Pro-protein convertase subtilisin-kexin 9(PCSK9)is known to affect low-density lipoprotein(LDL)metabolism, butthere are indications from severallines of research thatitmay also influence the metabolism of other lipoproteins,especially triglyceride-rich lipoproteins(TRL).This review summarizes the currentdata on this possible role of PCSK9.A link between PCSK9 and TRL has been suggested through the demonstration of(1)a correlation between plasma PCSK9 and triglyceride(TG)levels in health and disease,(2)a correlation between plasma PCSK9 and markers of carbohydrate metabolism,which is closely related to TG metabolism,(3)an effectof TG-lowering fibrate therapy on plasma PCSK9 levels,(4)an effectof PCSK9 on postprandiallipemia,(5)an effect of PCSK9 on adipose tissue biology,(6)an effectof PCSK9 on apolipoprotein B production from the liver and intestines,(7)an effectof PCSK9 on receptors otherthan low density lipoprotein receptor(LDLR)thatare involved in TRL metabolism,and(8)an effectofanti-PCSK9 therapy on serum TG levels.The underlying mechanisms are unclear butstarting to emerge.

    hyperlipidemia,hypercholesterolemia,molecular biology

    Introduction

    Pro-protein convertase subtilisin-kexin 9(PCSK9) belongs to a family of intracellular enzymes that convert inactive precursor proteins to active products. These products comprise a broad array of molecules, including hormones,receptors,growth factors and even otherenzymes[1].Yet,PCSK9 itselfis notknown to have an enzymatic role,otherthan to auto-catalytically cleave a pro-domain offitself.PCSK9 playsa role in liverregeneration[2],viralinfection[3]and neuronaldifferentiation[2], but since its discovery in 2003[2]and the demonstration of familialhypercholesterolemia(FH)in subjects with gain-of-function(GOF)PCSK9 mutations[4],the majority ofresearch has been done to elucidate its role in lipoprotein metabolism.

    PCSK9 ismosthighly expressed in the liver,intestine, brain and kidneys[2].Itis a secreted protein,mostly from the liver,and its levels are measurable in human plasma or serum[5-8].After reaching the circulation,itis delivered to thecellsurfaceoftissues,notably theliver,whereitbinds to the low density lipoprotein receptor(LDLR),prevents itsrecycling and instead promotesits lysosomaldegradation[9-11].Thisresultsin diminished uptakeofLDLparticles and elevation in LDL cholesterol(LDLC)levels.Thus, PCSK9 can be seen asa pro-atherogenic molecule.

    The PCSK9 precursorprotein hasa molecularweight of-74 kDa.Autocatalytic cleavage in the endoplasmicreticulum separates a-14 kDa prodomain from the-60 kDa mature PCSK9 protein.The prodomain remains associated with the rest of PCSK9 by non-covalent bonds and is essential for its role as a modulator of lipoprotein metabolism[12].The cleaved complex is transported through the Golgiapparatus and secreted[2]. Circulating PCSK9 binds to the EGF-A-like domain of hepatic LDLR[10]and escorts it from the endosomal recycling pathway to the lysosome for degradation[9], independent of its catalytic activity[13].There is also evidence for furin cleavage of a-7k Da segment, Ser153-Arg218,from the N-terminus of the catalytic domain.The-53k Da furin-cleaved PCSK9 has less LDLR degradation activity,possibly because of the loss of a region of PCSK9 required for LDLR binding as well as the concomitant loss of the-14k Da prodomain[14].Another study,however,has shown that furin cleavage did not result in dissociation of the pro-domain[15].

    The effecton the LDLR is the bestknown action of PCSK9,butthere are indications from severallines of research that PCSK9 may have other effects on lipoprotein metabolism.Here,we provide a review ofthe positive as well as contradictory data on the possible involvementof PCSK9 in the metabolism of triglyceride-rich lipoproteins(TRL),namely chylomicrons (CM),very low density lipoproteins(VLDL)and their remnants.

    Data on a possible role of PCSK9 in TRL metabolism

    Link between plasma PCSK9 and parameters of triglyceride metabolism

    One of the first hints at a link between PCSK9 and TRL metabolism was the demonstration of a positive correlation between plasma PCSK9 and plasma triglyceride(TG)levels[16-23].The correlation demonstrated in moststudies is modest(correlation coefficients of-0.25-0.3).This,however,is akin to the earlier finding of a correlation between plasma PCSK9 and LDLC levels,which prompted the subsequentelucidation of a mechanism for PCSK9's role in regulating LDLR-mediated clearance of LDL.Regarding the link to TG, investigation into possible mechanisms for PCSK9's role is currently underway.A cohesive model has not yetbeen arrived at.Itis noteworthy thatthere are some studies thatdo notshow this correlation[7,24].The reason for the discrepancy among studies is unclear.

    An importantrecentstudy wentbeyond TG levels to look atthe relationship between plasma PCSK9 and sub-fractions of VLDL and LDL.Plasma PCSK9 wasshown to predominantly relate to intermediate density lipoproteins(IDL),a TG-rich sub-fraction,which represents primarily VLDL remnants.Thisfinding suggests the possibility of PCSK9 having an effect on plasma TG via effects on the metabolism of VLDL and their remnants[22].

    Plasma PCSK9 concentration has also been evaluated via VLDL-TG kinetic studies using stable isotopes in non-diabetic butobese subjects.Here,the results provide no indication that PCSK9 has an impacton TRL metabolism as plasma PCSK9 concentrations did not correlate with VLDL-TG secretion or clearance[25].

    Link between plasma PCSK9 and parameters of triglyceride metabolism in disease states

    The positive correlation between plasma PCSK9 and TG levels has been found notjustin the generalpopulation but also in some specific disease states.

    In patients with proteinuria and chronic kidney disease(CKD)stages 2 and 3[26],and in those with CKD 5 on hemodialysis[27],PCSK9 levels correlate positively with TG levels[26].

    An intriguing observation regarding the relationship of PCSK9 and TG was the finding thatin members of four British families with the D374Y gain-of-function (GOF)PCSK9 mutation,which is linked to FH,TG levels were significantly higher(but still within reference range),as compared to controls[28].This suggests that a PCSK9 perturbation may have an impact on TRL metabolism.However,in a study on heterozygous FH(HeFH)and homozygous FH(HoFH)with identified LDLR mutations,TG levels were similar to those in controls[29].This discrepancy in findings may be due to a difference in underlying genetic defect and to the factthatplasma PCSK9 levels in the D374Y patients are low[30],while those in patients with LDLR mutations are high[29].

    Link between PCSK9 and diabetes and glucose metabolism

    Given the close association between glucose and TG metabolism,furthersupportfora link between PCSK9 and TG metabolism is emerging in the form of evidence that PCSK9 may have a role in glucose homeostasis.In one of the largestcohorts with plasma PCSK9 measurement,in addition to a positive correlation between plasma PCSK9 and TG,Lakoski etal.identified a significantcorrelation between plasma PCSK9 and fasting glucose,insulin and homeostasis model assessmentofinsulin resistance(HOMA-IR),a marker ofinsulin sensitivity[23].The same correlationswere found in a healthy adultpopulation[6],and a cohortof childrenand adolescents aged 9-16 years in a French Canadian population[17].Anothervery large population also demonstrated an association between plasma PCSK9 and plasma glucose and insulin levels[21].

    The mechanism of how PCSK9 affects glucose metabolism is still unclear.One study found that rat hepatocytes incubated with insulin for 24 hours had an increase in PCSK9 messenger RNA(mRNA)[31]. In human studies,a 24-hourinsulin infusion in a hyperinsulinemic glucose clamp experimentin healthy and diabetic(type 2)individuals had no effect on plasma PCSK9 levels[32],while a 3-hour euglycemic-hyperinsulinemic clamp study in non-diabetic postmenopausal obese patients actually decreased plasma concentrations of PCSK9[33].In addition,human liver-derived cell lines produced less PCSK9 protein and PCSK9 mRNA and secreted less PCSK9 into theirculture medium in response to the presence of insulin[33].

    Otherresearch found thatplasma PCSK9 levels were not different among patients with normal glucose metabolism,impaired glucose metabolism and type-2 diabetes mellitus[34].Also,no association was found between plasma PCSK9 levels and body mass index (BMI),waistcircumference,fatmass and fat-free mass, orvisceraland subcutaneousadipose tissue measured by computed tomography in abdominally obese men[16].

    Thus,there are differing data on the effectof insulin on the regulation of PCSK9 and on how insulin resistance affects PCSK9 status.Insulin action has major effectson TRL metabolism and more studies are needed to clearly determine its effect on PCSK9.It is possible that the putative link between PCSK9 and TG is the resultof the influence of insulin action on PCSK9.

    Conversely,the impactof PCSK9 deficiency on glucose metabolism also remains uncertain.In a study comparing wild-typ e to PCSK9 knockout mice, Mbikay etal.showed that knockoutmice had higher fasting plasma glucose,lower plasma insulin and higher glycemia on an oral glucose tolerance test[35]. However,another study failed to detect any alteration in glucose homeostasis in PCSK9-deficientmice[36].

    PCSK9 and fibrate therapy

    Fibrates are a class of medications used to treat hypertriglyceridemia,and they exert their action via the peroxisome proliferator-activated receptorα (PPAR-α)to increase peripheral TRL lipolysis via lipoprotein lipase,decrease intracellular lipolysis in adipose tissue and decrease secretion of VLDL[37].The demonstration of fibrate therapy having an effect on plasma PCSK9 levels raises the question of whether PCSK9 mediates some of the effects of fibrates on TRL metabolism.The picture,however,is unclear. Some studies have demonstrated a decrease in PCSK9 with fibrate use[7,38]while others have demonstrated an increase[8,39-41].A recentmeta-analysis looked at 6 studies and a total of 218 patients treated with fibrates for a period of 6 to 24 weeks.The conclusion was thatfibrate treatment,especially when compared to controls,significantly raised PCSK9 levels[42].In cell culture experiments,various fibrates were shown to repress PCSK9 expression in immortalized human hepatocytes[43].Beyond that,itis notknown how the fibrate-induced changes in PCSK9 influence TRL metabolism.It is also plausible,but unproven,that plasma PCSK9 changes are secondary to fibrateinduced changes in TRL metabolism.Further research is needed to clearly elucidate the link between fibrate treatmentand plasma PCSK9;the implications are relevantand interesting.

    PCSK9 and postprandial lipemia

    Postprandial lipemia(PPL)refers to the status of lipids and lipoproteins in blood following a fat load or a meal.Le May and his colleagues fed PCSK9 knockoutmice and theirwild-type littermates,a bolus of olive-oil.Attime zero,levels of TG were comparable;however,after 2 hours,the knockoutmice showed a significantly attenuated TG response.In addition,this study demonstrated that PCSK9 was highly expressed throughout the digestive tract and colon at levels equivalentto thatin the liver.Intestinallymph analysis revealed reduction in apoB,butnotTGoutput,resulting in larger TG-rich CM in knockoutmice compared to wild-type littermates.In addition,kinetic studies showed that PCSK9-deficient mice had an increased ability to clear CM compared to wild-type littermates. The study further demonstrated that the difference in observed TG levels in the knockoutmice was notdue to alterations in fat absorption,gastric emptying or intestinal transit[36].

    A few studies have looked at PCSK9’s relation to PPL in humans.The first,by Cariou et al.,found no change in PCSK9 levels following an oral fat load in a small10-patientsample.They also demonstrated that postprandialtriglyceride excursion was notaltered in 2 carriers of a PCSK9 loss-of-function(LOF)mutation compared with non-carriers[19].The second by Chan etal.looked at17 obese subjects who were given an oralfatload.They found thatin the postprandialperiod (totalof 24 hours post),PCSK9 was significantly associated with the area-under-the-curve for apoB-48 and inversely with the TG-apo B-48 fractional catabolic rate.They interpreted their findings as indicating thatcatabolism of TG and apoB-48-containing CM may be coordinated by PCSK9 in the postprandial state in obese individuals[20].

    Overall,data on the effectof PCSK9 on PPL,and of PPL on PCSK9,are very limited.Since the postprandialperiod is when TRL metabolism is most active, a demonstration of an effect of PCSK9 on indices of PPL would be an indication of an involvement of PCSK9 in TRL metabolism.

    PCSK9 and fat deposition

    Animalstudies have shown a link between PCSK9 and fat-deposition.Roubtsova and colleagues demonstrated that PCSK9 knockout mice accumulated 80% more visceralbody fat(perigonadaland perirenaldeposits)than wild-type mice.They subsequently showed that this was the result of adipocyte hypertrophy and increased fatuptake into adipose tissue via highercellsurface levels of very-low-density lipoprotein receptor (VLDLR;see below).Further ex-vivo models showed thatadipose,muscle and livertissue from knockoutmice had a higher rate of TG synthesis.Finally,they demonstrated the same effectin mice thatwere knockouts for both PCSK9 and LDLR,demonstrating that the effect they observed was LDLR-independent[44].

    A recentstudy by Mbikay etal.supported these findings;they also found that PCSK9 knockoutmice accumulated more perigonadalfat.Interestingly,they noted a greater effect in female mice fed a‘Western’high fatdiet[45].

    These findings provide evidence for a role o f PCSK9 in adipose tissue biology,which in turn could have a strong influence on overall TRL metabolism.

    PCSK9 effect on apolipoprotein B

    Effect of PCSK9 on ApoB in the liver

    Various cellculture and animalstudies have demonstrated a link between PCSK9 and apolipoprotein B (apo B)secretion from the liver.Rat hepatoma cells (McArdle-7777)overexpressing the GOF D374YPCSK9 mutant demonstrated increased secretion of apoB-containing lipoproteins[46].Similarly,mice overexpressing PCSK9 from a transgenic vectorhad higher plasma levels of both apoB100 and apoB48,and TG, and the effect was independent of the LDLR[47]. Interestingly,this study also provided data on the lack of effect of PCSK9 expression on genes governing cholesterol and TG biosynthesis[47],suggesting that PCSK9’s effecton TRL metabolism may be mediated mainly through an effecton apoB.Furthermore,studies showed that apo B100 secretion from primary hepatocytes of PCSK9 knockoutmice was reduced[48].

    There have also been some studies in human subjects on the effect of PCSK9 on apoB.It was shown in a stable isotope kinetic study that FH patients carrying the GOF S127R mutation in PCSK9 over-produce apo B-100(3-fold)along with overproduction of VLDL(3-fold),IDL(3-fold),and LDL(5-fold)[49]. Furthermore,Chernogubova et al.looked ata sample ofalmost6000 middle-aged subjects and found a significantcorrelation between serum PCSK9 and apoB[21].

    The link between PCSK9 and secretion of TRL has also been studied,although data are limited.Mice overexpressing PCSK9 were found to have increased hepatic VLDL production during fasting[50]and increased secretion of TRL into the serum[51].

    A possible mechanism by which PCSK9 may regulate apoB levelsis via the LDLR.Ithas been shown that intracellular LDLR protein can bind nascentapoB-containing lipoproteins and direct them for degradation[52]. It is therefore possible that when LDLR is depleted through the action ofPCSK9,apo-B isdegraded ata lesser rate.

    Other research has suggested that PCSK9 may affect apoB by stabilizing it and preventing its degradation. Using pulse chase experiments on primary hepatocytes from these mice over-expressing apoB,Sun etal.showed thatPCSK9 bindsto apoB via its N-terminusand protects it from undergoing autophagy.This effect was found to be independentofthe LDLR[47].Autophagy hasbeen previously demonstrated to be a means ofapoB degradation in hepatocytes,in addition to the lysosome pathway[47].

    Effect of PCSK9 on ApoB in the intestine

    Several studies have shown that human enterocytes treated with recombinanthuman PCSK9 demonstrated increased cellular and secreted apo B-48 and apoB-100[36,53,54].Levy etal.demonstrated in a human enterocyte cell line(Caco2/15 cells)that GOF D374YPCSK9 enhanced cholesterol uptake was associated with increased expression of cholesterol transporters NPC1L1 and CD36,and increased CM secretion through increased lipid and apo B48 biogenesis. PCSK9 silencing had the opposite effects.These responses were independent of the LDLR[53].

    Rashid etal.showed thatthe same cells,treated with recombinant human PCSK9,had increased production of TRL through both LDLR-dependent and LDLR-independe n t mecha n ism.Cellular and secreted apoB48 and apo B100 were enhanced.The increase in apoB was due to increased apoB mRNA transcription and enhanced apoB stability.In line with findings thatintracellular neutrallipids inhibitdegradation and enhance stability of apo B,they demonstrated thatPCSK9 treatment increased cellular neutral lipids via augmentation of levels of lipid-generating enzymes. They also demonstrated in mice that the levels and activity of intestinal microsomal triglyceride transfer protein(MTP),which transfers neutral lipids to apo B,is increased by PCSK9,again resulting in greater apoB stability.All of the demonstrated effects were reversed by short-term inhibition of PSCK9 via smallinterfering RNA(siRNA)[54].

    Taken together,these findings indicate that PCSK9 may be linked with production of apoB48 necessary for intestinal CM assembly.

    PCSK9 effect on other receptors in the LDLR family

    Effect of PCSK9 on VLDLR,apoE2 receptor and LRP-1

    Otherresearch has suggested thatPCSK9 may affect TRL metabolism via its effects on receptors other than LDLR.It has been shown that PCSK9 binds to 3 other members of the LDLR family;the VLDL receptor(VLDLR),apo E2 receptor(apoER2)[12,44,55],and LRP-1[56].These receptors show high homology with the LDLR;the VLDLR has 59%identity,and the apoE2 receptor has 46%identity with the LDLR[55]and the LRP-1,40%[14,56].When HEK293 cells(human embryonic kidney cell line)expressing VLDLR and apoER2 were incubated with conditioned media containing PCSK9,cellular levels of these receptors were decreased[55].Thus VLDLR and apoER2 are downregulated by PCSK9 and the mechanism is the same as for the LDLR,namely,redirection of receptors to the lysosomalcompartment for degradation[55].

    Both the VLDLR and apoER2 bind VLDL,but whether these receptors play a significant role in TG metabolism in humans is still unclear.Homozygous VLDLR knockoutmice had normalplasma lipoproteins but they had lower body weight and adipose tissue mass,indicating a possible role for VLDLR in storage of lipids in adipose tissue[57].This was further supported by the finding that when PCSK9 was added back to the knockoutmice,the expression of VLDLR protein in adipose tissue significantly decreased[44].

    LRP-1,on the otherhand,is known to play a major role in clearance of CM and VLDL remnants.While early studies suggested little link between LRP1 and PCSK9[9,14],subsequent research by Canuel et al. showed that PCSK9 could degrade LRP-1 and thatit competeswith the LDLR forPCSK9 activity[56].Apositive effect of PCSK9 on LRP-1 function would lend furthersupportfora role of PCSK9 in TRL metabolism. Effect of PCSK9 on CD36

    Finally,there is preliminary evidence that PCSK9 may target CD36,a scavenger receptor with multiple ligands and cellular functions,including facilitating cellular uptake of free fatty acids,though the results are contrasting.Roubtsova and her colleagues noted thatin PCSK9 knockoutmice,there was no effecton CD36 expression in perigonadalfat deposits of male mice,but that in females CD36 mRNA expression was increased by almost 80%in response to the loss of PCSK9[44].Similarly,Levy atal.showed thathuman enterocytes made to overexpress normal PCSK9,and the D374Y-PCSK9 GOF mutant,produce increased CD36[53].On the other hand,recent research by Demers noted that overexpression of PCSK9 led to the downregulation of CD36 in several cell lines, including adipoctyes[58].Whether PCSK9 targets CD36 for degradation or regulates it via a different mechanism requires further study;however,as CD36 has been linked to CM remnant clearance[59],its link to PCSK9 is relevantto further support PCSK9’s role in TRL metabolism.

    Effect of pharmacologic targeting of PCSK9 on TG

    LDL cholesterolis a well-established risk factor for cardiovascular disease and it is a primary target in lipid-lowering therapy.TRL have also been implicated in atherosclerosis[60].

    In light of the discovery of PCSK9’s effect on LDLC,ithas recently become a targetfor pharmaceutical intervention.Several different approaches have been explored to inhibit or reduce PCSK9 action.In human clinicaltrials,there has been most interest in antibodies against PCSK9 and two have been extensively studied;evolocumab and alirocumab are fully human monoclonal antibodies against PCSK9.The trials were designed to examine the effects of these novelmedications on LDLC,butseveralof them have reported on the effecton TG and VLDL.

    Trials have been done on patients withoutany known genetic predisposition towards dyslipidemia[61-69],and those with FH,both HeFH[70,71]and Ho FH[72-74].The reported effects on TRL have been mixed;severaltrials report no change in serum TG or VLDL cholesterol (VLDLC)levelwith treatment[61,65-68,70,72,73],while others demonstrate a significantlowering of these measured parameters[62-64,69,71,74].Interestingly,the majority of the positive trials tended to be larger,theirstudy population being generally between 300 and 900 patients[62-64,69,71,74], while the negative ones were smaller,with patientnumbers ranging from eightto 183[61,65,67,68,70,72,73],suggestingthatperhaps the negative trials lacked powerto demonstrate an effect.

    Stein etal.recently published a pooled analysis ofa totalof 1359 patients from 4 of the above-discussed trials and they showed that treatment with anti-PCSK9 antibodies sig nificantly lowered TG[75]. Overall,these findings further suggesta link between PCSK9 and TRL metabolism and hintatthe possibility of a novel therapy againsthypertriglyceridemia.

    Conclusions

    The effect of PCSK9 on LDL metabolism through promotion of LDLR degradation is well described. As more data are gathered,there are indications that PCSK9 may have additionalroles in other aspects of lipoprotein metabolism.This review focuses specifically on TRL metabolism.The pieces of evidence available are mostly observational and piecemeal.In some cases,the data are contradictory and uncertain. The available data seem also to suggestthatthe effect of PCSK9 on TRL metabolism is modest.No cohesive mechanistic model has been thus far been described. However,the existing data for a putative role of PCSK9 in TRL metabolism should be recognized and pursued further.It is encouraging that evidence to support a mechanism for the effect of PCSK9 on TRL metabolism is starting to emerge,especially in the area of PCSK9’s effect on intestinal production of TRL.As with the currentdevelopmentof treatment for elevated LDLC with anti-PCSK9 agents,itis possible that similar PCSK9-related strategies could be found for the treatment of hypertriglyceridemia.

    [1]Seidah NG,Sadr MS,Chr e′tien M,etal.Thee multifaceted proprotein convertases:their unique,redundant,complementary,and opposite functions[J].J Bio Chem,2013, 288(30):21473-21481.

    [2]Seidah NG,Benjannet S,WIckham L,etal.The secretory proprotein covertase neural Liver regeneration and neuronal differentiation[J].Proc Natl Acad Sci USA,2002, 100(3):928-933.

    [3]Labonte P,Begley S,G u′evin C,et al.PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression[J].Hepatology,2009,50(1):17-24.

    [4]Abifadel M,VarretM,Rabe`s JP,etal.Mutations in PCSK9 cause autosomal dominant hypercholesterolemia[J].Nat Genet,2003,34(2):154-156.

    [5]Alborn WE,Cao G,Careskey HE,etal.Serum proprotein convertase subtilisin kexin 9 is correlated directly with serum LDL cholesterol[J].Clin Chem,2007,53(10): 1814-1819.

    [6]Dubuc G,Tremblay M,Par e′G,et al.A new method for measurement of total plasma PCSK9:clinical applications[J].J Lipid Res,2010,51(1):140-149.

    [7]Lambert G,Ancellin N,Charlton F,et al.Plasma PCSK9 concentrations correlate with LDL and totalcholesterolin d iab etic p atients and are decreased by fenofibrate treatment[J].Clin Chem,2008,54(6):1038-1045.

    [8]Mayne J,Dewpura T,Raymon A,et al.Plasma PCSK9 levels are significantly modified by statins and fibrates in humans[J].Lipids Health Dis,2008,7(1):22.

    [9]Lagace TA,Curtis DE,Garuti R,et al.Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice[J].J Clin Invest,2006, 116(11):2995-3005.

    [10]Zhang DW,Lagace TA,Garuti R,et al.Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation[J].J Biol Chem,2007,282(25):1802-1812.

    [11]Nassoury N,Blasiole DA,Tebon Oler A,etal.The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR[J].Traffic, 2007,8(6):718-732.

    [12]Seidah NG,Awan Z,Chr e′tien M,et al.PCSK9:a key modulator of cardiovascular health[J].Circ Res,2014, 114(6):1022-1036.

    [13]Li J,Tumanut C,Gavigan JA,et al.Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity[J].Biochem J,2007,406(2):203-207.

    [14]Benjannet S,Rhainds D,Essalmani R,et al.NARC-1/ PCSK9 and its natural mutants:zymogen cleavage and effects on the low density lipoprotein(LDL)receptor and LDL cholesterl[J].J Biol Chem,2004,279(47): 48865-48875.

    [15]Han B,Eacho PI,Knierman MD,et al.Isolation and Characterization of the Circulating Truncated Form of PCSK9[J].J Lipid Res,2014,55(7):1505-1514.

    [16]Arsenault BJ,Pelletier-Beaumont E,Alm e′ras N,et al. PCSK9 levels in abdominally obese men:association with cardiometabolic risk profile and effects of a one-year lifestyle modification proram[J].Atherosclerosis,2014, 236(2):321-326.

    [17]Baass A,Dubuc G,Tremblay M,etal.Plasma PCSK9 is associated with age,sex,and multiple metabolic markers in a population-based sample of children and adolescents[J].Clin Chem,2009,55(9):1637-1645.

    [18]Brouwers MCGJ,van Greevenbroek MMJ,Konrad RJ, et al.Circulating PCSK9 is a strong determinant of plasma triacylglycerols and total cholesterol in homozygous carriers of apolipoprotein e2[J].Clin Sci(Lond), 2014,126(9):679-684.

    [19]Cariou B,LanghiC,Le Bras M,etal.Plasma PCSK9 concentrations during an oral fat load and after short term high-fat,high-fat high-protein and high-fructose diets[J]. Natr Metab(Lond),2013,10(1):4.

    [20]Chan DC,Wong ATY,Pang J,et al.Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects:a stable isotope study in the postprandialstate[J].Clin Sci(Lond)2015,128(6):379-385.

    [21]Chernogubova E,Strawbridge R,Mahdessian H,et al. Common and low-frequency genetic variants in the PCSK9 locus influence circulating PCSK9 levels[J]. Arterioscler Thromb Vasc Biol,2012,32(6):1526-1534.

    [22]Kwakernaak AJ,Lambert G,Dullaart RPF.Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins[J]. Clin Biochem,2014,47(7-8):679-682.

    [23]Lakoski SG,Lagace TA,Cohen JC,et al.Genetic and metabolic determinants of plasma PCSK9 levels[J]. J Clin Endocrinol Metab,2009,94(7):2537-2543.

    [24]Mayne J,Ooi TC,Raymond A,et al.Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations[J].Lipids Health Dis,2013,12(70).

    [25]Sullivan S,Fabbrini E,Horton JD,etal.Lack of relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people[J].Trans Res,2012, 158(5):302-306.

    [26]Kwakernaak AJ,Lambert G,Slag man MCJ,et al. Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects:relationship with lipoprotein response to antiproteinuric treatment[J].Atherosclerosis, 2013,226(2):459-465.

    [27]Abujrad H,Mayne J,Ruzicka M,et al.Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels[J].Atherosclerosis,2014,233(1): 123-129.

    [28]Naoumova RP,Tosi I,Patel D,et al.Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene:long-term follow-up and treatment response[J].Arterioscler Thromb Vasc Biol, 2005,25(12):2654-2660.

    [29]Raal F,Panz V,Immelman A,et al.Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy[J].J Am Heart Assoc,2013, 2(2):1-7.

    [30]Humphries SE,Neely RDG,Whittall RA,et al.Healthy individuals carrying the PCSK9 p.R46L variantand familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9[J].Clin Chem,2009,55(12):2153-2161.

    [31]Costet P,Cariou B,Labert G,et al.Hepatic PCSK9 expression is regulated by nutrtional status via insulin and sterol regulatory-element protein 1c[J].J Biol Chem, 2006,281(10):6211-6218.

    [32]Kapelle PJWH,Lambert G,Dullaart RPF.Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients[J].Atherosclerosis,2011,214(2):432-435.

    [33]Awan Z,Dubuc G,Faraj M,etal.The effectof insulin on circulating PCSK9 in postmenopausal obese women[J]. Clin Biochem,2014,47(12):1033-1039.

    [34]Brouwers MCGJ,Troutt JS,van Greevenbroek MMJ, et al.Plasma proprotein convertase subtilisin kexin type 9 is notaltered in subjects with impaired glucose metabolism and type 2 diabetes mellitus,butits relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus[J].Atherosclerosis,2011, 217(1):263-267.

    [35]Mbikay M,Sirois F,Mayne J,etal.PCSK9-deficientmice exhibit impaired glucose tolerance and pancreatic islet abnormalities[J].FEBS Lett,2010,584(4):701-706.

    [36]Le May C,Kourimate S,Langhi C,et al.Proprotein convertase subtilisin kexin type 9 null mice are protected from postp rand ial triglyceridemia[J].Arterioscler Thromb Vasc Biol,2009,29(5):684-690.

    [37]Malloy MJ,Kane JP.Fibric Acid Derivatives(Fibrates)-Mechanism of Action[J].In:Katzung BG,Editor.Basic and Clinical Pharmacology.10thedition.New York: McGraw Hill Lange,2007:569.

    [38]Chan DC,Hamilton SJ,Rye KA,etal.Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/ kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients[J]. Diabetes Obes Metab,2010,12(9):752-756.

    [39]Costet P,Hoffmann MM,Cariou B,etal.Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients[J].Atherosclerosis,2010, 212(1):246-251.

    [40]Noguchi T,Kobayashi J,Yagi K,et al.Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus:results from a crossover study[J].Atherosclerosis,2011,217(1): 165-170.

    [41]Troutt JS,Alborn WE,Cao G,etal.Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels[J].J Lipid Res,2010,51(2):345-351.

    [42]Sahebkar A.Circulating levels of proprotein convertase subtilisin kexin type 9 are elevated by fibrate therapy:a systematic review and meta-analysis of clinical trials[J]. Cardiol Rev.2014:22(6):306-312.

    [43]Kourimate S,Le May C,Langhi C,et al.Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9[J].J Biol Chem,2008, 283(15):9666-9673.

    [44]Roubtsova A,Munkonda MN,Awan Z,etal.Circulating proprotein convertase subtilisin/kexin 9(PCSK9)regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue[J].Arterioscler Thromb Vasc Bio, 2011,31(4):785-791.

    [45]Mbikay M,Sirois F,Gyamera-Acheampong C,et al. Variable effects of gender and Western diet on lipid and glucose homeostasis in aged PCSK9-deficient C57BL/6 mice CSK9PC57BL/6[J].J Diabetes,2015,7(1):74-84.

    [46]Sun XM,Eden ER,Tosi I,et al.Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia[J]. Hum Mol Genet,2005,14(9):1161-1169.

    [47]Sun H,SamarghandiA,Zhang N,etal.Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellulardegradation,irrespective ofthe low-density lipoprotein receptor[J].Arterioscler Thromb Vasc Biol,2012,32(7):1585-1595.

    [48]Rashid S,Curtis DE,Garuti R,et al.Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9[J].Proc Natl Acad Sci USA,2005,102(15):5374-5379.

    [49]Ouguerram K,Chetiveaux M,Zair Y,et al.Apolipoprotein B100 metabolism in autosomal-dominanthypercholesterolemia related to mutations in PCSK9[J].Arterioscler Thromb Vasc Biol,2004,24(8):1448-1453.

    [50]Lambert G,Jarnoux AL,Pineau T,et al.Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9:lack of modulation ofvery-low-density lipoprotein hepatic output by the lowdensity lipoprotein receptor[J].Endocrinology,2006, 14(10)7:4985-4995.

    [51]Tavori H,Fan D,Blakemore JL,et al.Serum proprotein convertase subtilisin/kexin type 9 and cell surface lowdensity lipoprotein receptor:evidence for a reciprocal regulation[J].Circulation,2013,127(24):2403-2413.

    [52]Blasiole DA,Oler AT,Attie AD.Regulation of ApoB secretion by the low density lipoprotein receptor requires exit from the endoplasmic reticulum and interaction with ApoE or ApoB[J].J BiolChem,2008,283(17):11374-11381.

    [53]Levy E,Ben Djoudi Ouadda A,Spahis S,et al.PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells[J].Atherosclerosis,2013,227(2):297-306.

    [54]Rashid S,Tavori H,Brown PE,et al.Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and-independent mechanisms[J].Circulation,2014, 130(5):431-441.

    [55]Poirier S,Mayer G,Benjannet S,et al.The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor(LDLR)and its closest family members VLDLR and ApoER2[J].J Biol Chem,2008, 283(4):2363-2372.

    [56]Canuel M,Sun X,Asselin MC,et al.Proprotein convertase subtilisin/kexin type 9(PCSK9)can mediate degradation of the low density lipoprotein receptor-related protein 1(LRP-1)[J].PLoS One,2013,8(5):e64145.

    [57]Frykman PK,Brown MS,Yamamoto T,et al.Normal plasma lipoproteins and fertility in gene-targeted mice homozygous for a disruption in the gene encoding very low density lipoprotein receptor[J].Proc Natl Acad Sci USA,1995,92(18):8453-8457.

    [58]Demers A,Lauzier B,Des Rosiers C,et al.Proprotein Convertase Subtilisin/kexin Type 9(PCSK9)Targets the CD36 Receptor for Degradation[J].Arterioscler Thromb Vasc Biol.2013,33(5):A77.

    [59]Masuda D,Hirano K,Oku H,et al.Chylomicron remnants are increased in the postprandial state in CD36 deficiency[J].J Lipid Res,2009,50(5):999-1011.

    [60]Ooi TC,Ooi DS.The atherogenic significance of an elevated plasma triglyceride level[J].Crit Rev Clin Lab Sci,1998,35(6):489-516.

    [61]Dias CS,Shaywitz AJ,Wasserman SM,et al.Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels[J].J Am Coll Cardiol,2012,60(19):1888-1898.

    [62]Giugliano RP,Desai NR,Kohli P,et al.Efficacy,safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia(LAPLACETIMI 57):a randomised,placebo-controlled,dose-ranging, phase-2 study[J].Lancet,2007,380(9858):2007-2017.

    [63]Hirayama A,Honarpour N,Yoshida M,et al.Effects of Evolocumab(AMG 145),a Monoclonal Antibody to PCSK9,in Hypercholesterolemic,Statin-Treated Japanese Patien ts at High Card iov ascu lar Risk[J].Circ J, 2014,78(5):1073-1082.

    [64]Koren MJ,Lundqvist P,Bolognese M,etal.Anti-PCSK9 Monotherapy for Hypercholesterolemia Clinical Trial of Evolocumab[J].J Am Coll Cardiol,2014,63(23):2531-2540.

    [65]Mckenney JM,Harm PD,Korem MJ,et al.Safety and Efficacy of a Monoclonal Antibody to Prop rotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727,in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy[J].J Am Coll Cardiol,2012,59(25):2344-2353.

    [66]Robinson JG,Nedergaard BS,Rogers WJ,etal.Effectof Evolocumab or Ezetimibe Added to Moderate-or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia The LAPLACE-2 Randomized Clinical Trial[J].JAMA,2014,311(18):1870-1882.

    [67]Roth EM,Taskinen M,Ginsberg HN,etal.Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia:Results of a 24 week double-blind,randomized Phase 3 trial[J].Int J Cardiol, 2014,176(1):55-61.

    [68]Sullivan D,Olsson AG,Scott R,et al.Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol[J].JAMA.2014:308(23);2497-2506.

    [69]Blom DJ,Hala T,Bolognese M,etal.A 52-week placebocontrolled trial of evolocumab in hyperlipidemia[J].N Engl J Med,2014,370(19):1809-1819.

    [70]Stein EA,Gipe D,Bergeron J,et al.Effect of a monoclonal antibody to PCSK9,REGN727/SAR236553,to reduce low-density lipoprotein cholesterolin patients with heterozygous familialhypercholesterolaemia on stable statin dose with or withoutezetimibe therapy:a phase 2 randomised controlled trial[J].Lancet,2012,380(9836): 29-36.

    [71]Raal F,Scott R,Somaratn e R,et al.Low-Den sity Lipoprotein Cholesterol-Lowering Effects of AMG 145,a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia[J].Circulation,2012,126(20):2408-2417.

    [72]Stein EA,Honarpour N,Wasserman SM,et al.Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody,AMG 145,in Homozygous Familial Hypercholesterolemia[J].Circulation,2013,128(19): 2113-2120.

    [73]Raal FJ,Honarpour N,Blom DJ,et al.Inhibition of PCSK9 with evolocumab in ho mozyg ous familial hypercholesterolaemia(TESLA Part B):a randomised, double-blind,placebo-controlled trial[J].Lancet,2015, 385(9965):341-350.

    [74]RaalFJ,Stein EA,etal.PCSK9 inhibition with evolocumab (AMG 145)in heterozygous familialhypercholesterolaemia (RUTHERFORD-2):a randomised,double-blind,placebocontrolled trial[J].Lancet,2015,385(9965):331-340.

    [75]Stein EA,Giugliano RP,Koren MJ,et al.Efficacy and safety of evolocumab(AMG 145),a fully human monoclonal antibody to PCSK9,in hyperlipidaemic patients on various background lipid therapies?:pooled analysis of 1359 patients in four phase 2 trials[J].Eur Heart J, 2014,35(33):2249-2259.

    ?Corresponding author:Dr.T C Ooi,The Ottawa Hospital-Riverside Campus,1967 Riverside Drive,Ottawa,Ontario K1H 7W9,Canada, Tel:(613)738 8400 Ext.81950,E-mail:tcooi@toh.on.ca.

    Received 30 March 2015,Accepted 01 July 2015,Epub 20 July 2015

    R589.2,Document code:A

    The authors reported no conflict of interests.

    ?2015 by the Journal of Biomedical Research.All rights reserved.

    10.7555/JBR.29.20150052

    日本与韩国留学比较| 日本熟妇午夜| 免费观看精品视频网站| 看免费av毛片| 欧美日本视频| 神马国产精品三级电影在线观看| 99在线人妻在线中文字幕| 最近最新免费中文字幕在线| 蜜桃久久精品国产亚洲av| 18+在线观看网站| 麻豆久久精品国产亚洲av| 亚洲美女视频黄频| 日韩欧美精品免费久久 | 久久久久免费精品人妻一区二区| 老熟妇仑乱视频hdxx| 国产精品,欧美在线| 久久天躁狠狠躁夜夜2o2o| 精品午夜福利视频在线观看一区| 中文资源天堂在线| 久久国产乱子伦精品免费另类| 丰满乱子伦码专区| 欧美日韩福利视频一区二区| 真人做人爱边吃奶动态| 日韩人妻高清精品专区| 综合色av麻豆| 精品欧美国产一区二区三| 日韩亚洲欧美综合| 亚洲专区国产一区二区| 欧美一区二区精品小视频在线| 国产老妇女一区| 久久久久久九九精品二区国产| 最好的美女福利视频网| 免费看a级黄色片| 1000部很黄的大片| 亚洲激情在线av| 精品免费久久久久久久清纯| 欧美丝袜亚洲另类 | 国产高清视频在线观看网站| 久久性视频一级片| 亚洲人成网站高清观看| 亚洲精品在线美女| 男女床上黄色一级片免费看| 男人的好看免费观看在线视频| 亚洲国产中文字幕在线视频| 熟妇人妻久久中文字幕3abv| 日韩人妻高清精品专区| 国产成人系列免费观看| 观看美女的网站| 国产麻豆成人av免费视频| 久久久久精品国产欧美久久久| 久久久久免费精品人妻一区二区| 伊人久久大香线蕉亚洲五| 波多野结衣高清作品| 嫩草影院入口| 亚洲第一欧美日韩一区二区三区| 亚洲无线观看免费| 亚洲精品亚洲一区二区| 免费大片18禁| 欧美丝袜亚洲另类 | 免费人成在线观看视频色| av在线蜜桃| 男女床上黄色一级片免费看| 久99久视频精品免费| 人妻丰满熟妇av一区二区三区| 成年女人看的毛片在线观看| 99热只有精品国产| 黄片大片在线免费观看| 欧美最黄视频在线播放免费| 神马国产精品三级电影在线观看| 亚洲欧美日韩卡通动漫| 精品人妻一区二区三区麻豆 | 性色av乱码一区二区三区2| 97超级碰碰碰精品色视频在线观看| 日韩欧美在线乱码| 少妇丰满av| 乱人视频在线观看| 一本久久中文字幕| 国产av在哪里看| 国产免费一级a男人的天堂| 久久精品91蜜桃| 我的老师免费观看完整版| 亚洲精品日韩av片在线观看 | 1000部很黄的大片| 亚洲中文字幕一区二区三区有码在线看| 成人av一区二区三区在线看| ponron亚洲| 午夜福利在线在线| 国产午夜精品久久久久久一区二区三区 | 亚洲国产精品久久男人天堂| 校园春色视频在线观看| 久久久精品大字幕| 亚洲va日本ⅴa欧美va伊人久久| 老汉色∧v一级毛片| av国产免费在线观看| 免费观看人在逋| 蜜桃亚洲精品一区二区三区| 久久精品91蜜桃| 久久精品影院6| 三级毛片av免费| 国产伦在线观看视频一区| 无遮挡黄片免费观看| 性色av乱码一区二区三区2| 一卡2卡三卡四卡精品乱码亚洲| 国内精品一区二区在线观看| 搡女人真爽免费视频火全软件 | 久久精品国产综合久久久| 午夜免费成人在线视频| 两个人视频免费观看高清| 校园春色视频在线观看| 亚洲成人久久性| 久久精品综合一区二区三区| 欧美色欧美亚洲另类二区| 91九色精品人成在线观看| 欧美在线黄色| 一边摸一边抽搐一进一小说| 日日摸夜夜添夜夜添小说| 此物有八面人人有两片| 嫩草影院精品99| 欧美中文日本在线观看视频| 在线观看免费视频日本深夜| or卡值多少钱| 日韩欧美在线二视频| 亚洲电影在线观看av| 99在线人妻在线中文字幕| 亚洲人与动物交配视频| 99久久九九国产精品国产免费| 久久婷婷人人爽人人干人人爱| www.www免费av| 国产成人av激情在线播放| 三级国产精品欧美在线观看| 香蕉丝袜av| 欧洲精品卡2卡3卡4卡5卡区| 1000部很黄的大片| 欧美在线一区亚洲| 淫妇啪啪啪对白视频| 日韩人妻高清精品专区| 欧美成人a在线观看| 欧美大码av| ponron亚洲| 观看美女的网站| 久久久国产成人精品二区| 脱女人内裤的视频| 午夜久久久久精精品| 制服丝袜大香蕉在线| 中亚洲国语对白在线视频| 亚洲精品亚洲一区二区| 人妻夜夜爽99麻豆av| 小说图片视频综合网站| ponron亚洲| 精品国产三级普通话版| 亚洲精品色激情综合| 99国产综合亚洲精品| 中亚洲国语对白在线视频| 国产成人欧美在线观看| 亚洲在线观看片| 日韩欧美在线乱码| 999久久久精品免费观看国产| eeuss影院久久| 国产一区二区三区在线臀色熟女| 波野结衣二区三区在线 | 哪里可以看免费的av片| 国内揄拍国产精品人妻在线| 久久中文看片网| 亚洲av一区综合| 成年人黄色毛片网站| 色综合欧美亚洲国产小说| 精品一区二区三区av网在线观看| 欧美绝顶高潮抽搐喷水| 老熟妇仑乱视频hdxx| 久久久久久久久大av| 国产黄色小视频在线观看| 久9热在线精品视频| 成人亚洲精品av一区二区| 久久精品国产综合久久久| 亚洲人成网站在线播放欧美日韩| 五月伊人婷婷丁香| 偷拍熟女少妇极品色| 熟女人妻精品中文字幕| 少妇高潮的动态图| 九九热线精品视视频播放| 亚洲精品456在线播放app | 国产精品亚洲美女久久久| 搡女人真爽免费视频火全软件 | 亚洲 欧美 日韩 在线 免费| 国产黄色小视频在线观看| 亚洲天堂国产精品一区在线| 久久人人精品亚洲av| 欧美xxxx黑人xx丫x性爽| 国产激情偷乱视频一区二区| 午夜福利欧美成人| 欧美日韩一级在线毛片| av福利片在线观看| 叶爱在线成人免费视频播放| 国产精品电影一区二区三区| 国产伦精品一区二区三区视频9 | 网址你懂的国产日韩在线| 十八禁网站免费在线| 在线看三级毛片| 婷婷精品国产亚洲av| 女生性感内裤真人,穿戴方法视频| 国产精品久久久久久久久免 | 精品人妻1区二区| 夜夜爽天天搞| netflix在线观看网站| 男女做爰动态图高潮gif福利片| 欧美乱妇无乱码| 亚洲无线观看免费| 女生性感内裤真人,穿戴方法视频| 色综合欧美亚洲国产小说| 每晚都被弄得嗷嗷叫到高潮| 99国产精品一区二区蜜桃av| 国产亚洲精品综合一区在线观看| 亚洲美女视频黄频| 狂野欧美激情性xxxx| 成年女人看的毛片在线观看| 欧美激情在线99| 脱女人内裤的视频| 色吧在线观看| 欧洲精品卡2卡3卡4卡5卡区| 少妇人妻一区二区三区视频| 成年人黄色毛片网站| 久久精品亚洲精品国产色婷小说| 国产精品日韩av在线免费观看| 欧美中文综合在线视频| 色在线成人网| 国产中年淑女户外野战色| 好看av亚洲va欧美ⅴa在| 久久久久亚洲av毛片大全| 免费人成视频x8x8入口观看| 亚洲国产精品久久男人天堂| av在线蜜桃| 免费人成视频x8x8入口观看| 搞女人的毛片| 国产精品三级大全| 中文在线观看免费www的网站| 97碰自拍视频| 免费观看的影片在线观看| 久久精品亚洲精品国产色婷小说| 天堂动漫精品| 最近最新中文字幕大全电影3| 欧美av亚洲av综合av国产av| 国产成人av教育| 国产黄片美女视频| 一个人免费在线观看电影| 精品久久久久久久久久免费视频| av欧美777| 黄色片一级片一级黄色片| 亚洲专区国产一区二区| 亚洲av第一区精品v没综合| 国产av麻豆久久久久久久| 午夜a级毛片| 在线免费观看不下载黄p国产 | 色老头精品视频在线观看| 久久精品影院6| svipshipincom国产片| 日韩欧美国产一区二区入口| 欧美日韩一级在线毛片| 三级国产精品欧美在线观看| 亚洲精品久久国产高清桃花| 欧美激情久久久久久爽电影| 搡老妇女老女人老熟妇| 9191精品国产免费久久| 麻豆国产97在线/欧美| 欧美国产日韩亚洲一区| www日本黄色视频网| 美女 人体艺术 gogo| 欧美区成人在线视频| 亚洲av成人av| 欧美xxxx黑人xx丫x性爽| 国产单亲对白刺激| 亚洲av五月六月丁香网| 欧美在线黄色| 国产精品女同一区二区软件 | 88av欧美| 99国产精品一区二区蜜桃av| 很黄的视频免费| 在线十欧美十亚洲十日本专区| 精品国产美女av久久久久小说| 亚洲熟妇熟女久久| 午夜福利在线观看免费完整高清在 | 久久精品综合一区二区三区| 国产欧美日韩一区二区精品| 国产探花在线观看一区二区| 老司机在亚洲福利影院| 日本 av在线| 女人十人毛片免费观看3o分钟| 亚洲第一欧美日韩一区二区三区| 在线国产一区二区在线| 国产不卡一卡二| 99国产综合亚洲精品| 日本撒尿小便嘘嘘汇集6| 一个人看视频在线观看www免费 | 搡老熟女国产l中国老女人| 国产国拍精品亚洲av在线观看 | 国产成人系列免费观看| 性欧美人与动物交配| 日韩精品青青久久久久久| 日本一二三区视频观看| 日本成人三级电影网站| 99国产精品一区二区蜜桃av| 又黄又爽又免费观看的视频| а√天堂www在线а√下载| 9191精品国产免费久久| 最近视频中文字幕2019在线8| 国产精品一区二区免费欧美| 97超视频在线观看视频| 男女那种视频在线观看| 亚洲av美国av| 最近最新中文字幕大全电影3| 国内揄拍国产精品人妻在线| www国产在线视频色| 欧美+亚洲+日韩+国产| 亚洲最大成人手机在线| 日韩中文字幕欧美一区二区| 亚洲精品久久国产高清桃花| 熟女电影av网| 美女cb高潮喷水在线观看| 波野结衣二区三区在线 | 欧美乱码精品一区二区三区| 午夜福利免费观看在线| 人人妻人人看人人澡| 九色成人免费人妻av| 亚洲天堂国产精品一区在线| 免费电影在线观看免费观看| 欧美国产日韩亚洲一区| 丰满的人妻完整版| 制服人妻中文乱码| 久久久久久久久久黄片| 久久国产精品人妻蜜桃| 美女黄网站色视频| 久久人妻av系列| 国产精品av视频在线免费观看| 亚洲欧美精品综合久久99| 女人高潮潮喷娇喘18禁视频| 精品无人区乱码1区二区| 国产一区二区三区视频了| 桃红色精品国产亚洲av| 国产99白浆流出| 成人无遮挡网站| 色老头精品视频在线观看| 51午夜福利影视在线观看| 小蜜桃在线观看免费完整版高清| 国产精品日韩av在线免费观看| 免费人成在线观看视频色| 精品乱码久久久久久99久播| 高清在线国产一区| 国产免费av片在线观看野外av| 老司机福利观看| 亚洲精品成人久久久久久| 桃色一区二区三区在线观看| 亚洲av成人不卡在线观看播放网| 97超级碰碰碰精品色视频在线观看| 此物有八面人人有两片| 在线免费观看不下载黄p国产 | 成年女人看的毛片在线观看| tocl精华| 日韩免费av在线播放| 久99久视频精品免费| 欧美一区二区精品小视频在线| 久久九九热精品免费| 欧美三级亚洲精品| 成年人黄色毛片网站| 亚洲精品在线美女| 别揉我奶头~嗯~啊~动态视频| 国产午夜福利久久久久久| 给我免费播放毛片高清在线观看| 国产一级毛片七仙女欲春2| 最后的刺客免费高清国语| 少妇高潮的动态图| 一边摸一边抽搐一进一小说| 国产极品精品免费视频能看的| 午夜老司机福利剧场| 中文亚洲av片在线观看爽| 国模一区二区三区四区视频| 午夜福利在线观看免费完整高清在 | 可以在线观看的亚洲视频| 色哟哟哟哟哟哟| 亚洲成av人片免费观看| 精品国产亚洲在线| 好男人在线观看高清免费视频| 两个人的视频大全免费| 非洲黑人性xxxx精品又粗又长| 91久久精品电影网| 狂野欧美白嫩少妇大欣赏| 日本免费一区二区三区高清不卡| 国产成人av教育| 国产精品影院久久| 蜜桃亚洲精品一区二区三区| 中文字幕人成人乱码亚洲影| 亚洲avbb在线观看| 久久亚洲精品不卡| 国产 一区 欧美 日韩| 宅男免费午夜| 99热精品在线国产| 欧美一区二区国产精品久久精品| 久久久久免费精品人妻一区二区| 岛国在线免费视频观看| 女同久久另类99精品国产91| 好男人在线观看高清免费视频| 国产高潮美女av| 女警被强在线播放| 欧美又色又爽又黄视频| 欧美3d第一页| 精品久久久久久,| 嫁个100分男人电影在线观看| 看免费av毛片| 又粗又爽又猛毛片免费看| 男女之事视频高清在线观看| 国产在线精品亚洲第一网站| 午夜福利18| 久久九九热精品免费| 搡老熟女国产l中国老女人| 精品乱码久久久久久99久播| 免费在线观看亚洲国产| 黄色成人免费大全| 免费看美女性在线毛片视频| 国产成人a区在线观看| av欧美777| 国产97色在线日韩免费| 久久久久亚洲av毛片大全| 亚洲最大成人手机在线| 激情在线观看视频在线高清| 亚洲av日韩精品久久久久久密| 一本精品99久久精品77| 欧美在线黄色| av片东京热男人的天堂| ponron亚洲| 久久九九热精品免费| h日本视频在线播放| 国内毛片毛片毛片毛片毛片| 中文字幕久久专区| 久久这里只有精品中国| 免费在线观看亚洲国产| 午夜福利在线观看吧| svipshipincom国产片| 91久久精品电影网| 九九热线精品视视频播放| 国产 一区 欧美 日韩| 最新中文字幕久久久久| 国产97色在线日韩免费| 国产精品综合久久久久久久免费| 日本 欧美在线| 757午夜福利合集在线观看| 国产精品爽爽va在线观看网站| 级片在线观看| 一区福利在线观看| 嫩草影院精品99| 俺也久久电影网| h日本视频在线播放| 国产精品久久视频播放| 久久久久国产精品人妻aⅴ院| 欧美日韩乱码在线| 成人永久免费在线观看视频| 女同久久另类99精品国产91| 午夜免费观看网址| 校园春色视频在线观看| avwww免费| 黄色片一级片一级黄色片| 三级国产精品欧美在线观看| 国产精华一区二区三区| 一级黄色大片毛片| 免费搜索国产男女视频| 免费看光身美女| av视频在线观看入口| 天天一区二区日本电影三级| 亚洲欧美一区二区三区黑人| 色老头精品视频在线观看| 欧美黑人巨大hd| 熟妇人妻久久中文字幕3abv| 亚洲欧美一区二区三区黑人| 激情在线观看视频在线高清| 91在线精品国自产拍蜜月 | 日韩欧美三级三区| 精品久久久久久久久久久久久| 男女做爰动态图高潮gif福利片| 欧美国产日韩亚洲一区| 丰满的人妻完整版| 亚洲天堂国产精品一区在线| 国产伦精品一区二区三区视频9 | 日韩人妻高清精品专区| 午夜激情福利司机影院| 女人高潮潮喷娇喘18禁视频| 亚洲精品456在线播放app | 亚洲欧美日韩东京热| а√天堂www在线а√下载| 99久久九九国产精品国产免费| 久久精品91无色码中文字幕| 三级男女做爰猛烈吃奶摸视频| 国产精品久久久久久人妻精品电影| 国产精品乱码一区二三区的特点| 狠狠狠狠99中文字幕| 欧美日韩国产亚洲二区| 超碰av人人做人人爽久久 | 99久久精品热视频| 亚洲精品乱码久久久v下载方式 | svipshipincom国产片| 午夜免费观看网址| 国产又黄又爽又无遮挡在线| 亚洲熟妇中文字幕五十中出| 啦啦啦观看免费观看视频高清| 亚洲av日韩精品久久久久久密| 99久久99久久久精品蜜桃| 色综合站精品国产| 国产伦精品一区二区三区四那| 国产成人福利小说| 窝窝影院91人妻| 欧美一区二区国产精品久久精品| 日韩欧美在线乱码| 欧美性感艳星| 亚洲最大成人中文| 欧美黑人巨大hd| 国产视频一区二区在线看| 青草久久国产| 免费在线观看影片大全网站| 在线观看日韩欧美| 中文字幕av成人在线电影| 国内精品久久久久久久电影| 亚洲欧美日韩无卡精品| 欧美日韩亚洲国产一区二区在线观看| 国产蜜桃级精品一区二区三区| 欧美一级毛片孕妇| 午夜a级毛片| 日本三级黄在线观看| 久久99热这里只有精品18| 国产av一区在线观看免费| 亚洲激情在线av| 国产综合懂色| 亚洲av美国av| 一级毛片女人18水好多| 久久香蕉国产精品| 91在线观看av| av视频在线观看入口| 麻豆成人av在线观看| tocl精华| 男人舔奶头视频| 国产单亲对白刺激| 久久婷婷人人爽人人干人人爱| 国产色爽女视频免费观看| 亚洲精品美女久久久久99蜜臀| 欧美最黄视频在线播放免费| 波多野结衣高清作品| 欧美一级a爱片免费观看看| 国产黄a三级三级三级人| 国产熟女xx| 欧美zozozo另类| 国产视频一区二区在线看| 亚洲五月婷婷丁香| 一进一出抽搐gif免费好疼| 好男人在线观看高清免费视频| 亚洲一区二区三区色噜噜| 18禁黄网站禁片午夜丰满| 亚洲真实伦在线观看| 蜜桃亚洲精品一区二区三区| 国产午夜精品久久久久久一区二区三区 | 国产精品一及| 成熟少妇高潮喷水视频| 国产欧美日韩一区二区三| 欧美大码av| 免费高清视频大片| 精品久久久久久久人妻蜜臀av| 最近视频中文字幕2019在线8| 9191精品国产免费久久| 精品免费久久久久久久清纯| 欧美绝顶高潮抽搐喷水| 亚洲国产精品成人综合色| 国语自产精品视频在线第100页| 国产精品久久久久久人妻精品电影| 欧美不卡视频在线免费观看| www.www免费av| 国产精品亚洲一级av第二区| 1024手机看黄色片| 1000部很黄的大片| 麻豆成人午夜福利视频| 亚洲 国产 在线| 97超级碰碰碰精品色视频在线观看| 久久国产乱子伦精品免费另类| 成人鲁丝片一二三区免费| eeuss影院久久| av黄色大香蕉| 亚洲精品国产精品久久久不卡| 亚洲国产欧美网| 国产黄色小视频在线观看| 老司机在亚洲福利影院| 性色avwww在线观看| 亚洲中文字幕一区二区三区有码在线看| 成人性生交大片免费视频hd| 女人高潮潮喷娇喘18禁视频| 成人亚洲精品av一区二区| 18禁国产床啪视频网站| 国产激情欧美一区二区| 欧美性猛交╳xxx乱大交人| 天天一区二区日本电影三级| 黄片大片在线免费观看| 欧美+亚洲+日韩+国产| www国产在线视频色| 色综合亚洲欧美另类图片| 欧美一级a爱片免费观看看| or卡值多少钱| 免费无遮挡裸体视频| 久久性视频一级片| 亚洲av成人不卡在线观看播放网| 老司机福利观看| 欧美黄色片欧美黄色片| 日韩欧美在线乱码| 亚洲aⅴ乱码一区二区在线播放| 成年女人看的毛片在线观看| 一级黄片播放器| 啦啦啦免费观看视频1| 国产高清videossex| 欧美一区二区国产精品久久精品| 在线十欧美十亚洲十日本专区| 日本一二三区视频观看| 婷婷精品国产亚洲av在线| 亚洲avbb在线观看| 亚洲熟妇中文字幕五十中出|